
|Slideshows|August 17, 2017
Odor Identification: Marker for Early Alzheimer Disease?
Author(s)Veronica Hackethal, MD
OI may serve for research purposes as a simple and inexpensive indicator of evolving AD pathology. Details here.
Advertisement
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
3
New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease
4
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
5


































